Form 4: CareDx Director Christine Cournoyer Reports Acquisition of Restricted Stock Units

CareDx, Inc. Director Christine Cournoyer has reported the acquisition of 12,103 shares of common stock in the form of restricted stock units, increasing her beneficial ownership.

Summary

• Christine Cournoyer, a Director of CareDx, Inc. (CDNA), acquired 12,103 shares of common stock.
• The acquisition occurred on June 13, 2025, at a price of $0.00 per share, indicating a grant of restricted stock units (RSUs).
• Following this transaction, Ms. Cournoyer beneficially owns 49,148 shares of CareDx common stock.
• The acquired restricted stock units are scheduled to vest in one installment on the earlier of June 13, 2026, or the day immediately prior to the first annual meeting of stockholders held by CareDx, Inc. after June 13, 2025.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as it indicates a director receiving equity compensation, aligning their interests with shareholders, which is a standard and generally favorable practice. It's not highly impactful but signals continued commitment.

Positives

• The acquisition of 12,103 restricted stock units by Director Christine Cournoyer indicates continued alignment of management interests with shareholder interests.
• The increase in beneficial ownership to 49,148 shares demonstrates the director's ongoing stake in the company's performance.

Negatives

• The document does not contain any explicitly negative information.

Risks

• The value of the restricted stock units is subject to the future market price of CareDx, Inc. common stock.
• Vesting of the restricted stock units is contingent upon continued service as a director until the vesting date.

Future Outlook

The vesting schedule for the restricted stock units indicates future milestones for the director's equity compensation, with vesting expected by June 13, 2026, or earlier based on the company's annual meeting schedule.

Industry Context

This Form 4 filing is a routine disclosure of insider stock ownership changes, common across all publicly traded companies. It reflects standard compensation practices for directors, often involving equity grants to align their interests with long-term shareholder value, particularly in the biotechnology and healthcare diagnostics sector where CareDx operates.

Comparison to Industry Standards

• The grant of restricted stock units to a director at a $0.00 acquisition price is a standard practice for non-cash equity compensation in publicly traded companies, including those in the biotech and healthcare diagnostics industry.
• This aligns with common corporate governance practices aimed at incentivizing long-term performance and retention of key personnel.
• Specific comparable companies or projects are not detailed in this filing, as it focuses solely on an individual's transaction.

Stakeholder Impact

• Shareholders: The grant of RSUs to a director aligns their interests with shareholders, potentially encouraging long-term value creation.

Next Steps

• Vesting of the 12,103 restricted stock units on the earlier of June 13, 2026, or the day immediately prior to the first annual meeting of stockholders held by CareDx, Inc. after June 13, 2025.

Key Dates

Keywords

CareDx, CDNA, SEC Form 4, Insider Trading, Restricted Stock Units, RSU Grant, Director Compensation, Beneficial Ownership, Stock Ownership